Cardiac resynchronisation therapy in 2015: keeping up with the pace
A Voskoboinik1,2, A D McGavigan3, J A Mariani2,4
1Department of Cardiology, Western Hospital, Melbourne, Victoria, Australia.
Internal Medicine Journal
|April 9, 2015
Summary
Cardiac resynchronisation therapy (CRT) improves heart failure outcomes by refining patient selection and utilizing advanced imaging. New lead technologies promise further advancements in treating this widespread condition.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Heart failure (HF) remains a significant global health challenge, increasing morbidity and mortality.
- Cardiac resynchronisation therapy (CRT), or biventricular pacing, is a key treatment for HF.
- Evolving understanding of HF pathophysiology necessitates updated treatment strategies.
Purpose of the Study:
- To review recent advancements in CRT for heart failure management.
- To discuss changes in patient selection criteria for CRT.
- To explore emerging technologies and imaging modalities in CRT.
Main Methods:
- Analysis of current literature and guideline updates on CRT.
- Review of data on CRT in specific patient populations (e.g., atrial fibrillation, pacemaker-dependent).
- Examination of the role of multimodality imaging in CRT patient selection and lead placement.
Main Results:
- Updated guidelines emphasize improved patient selection to reduce CRT non-response rates.
- CRT efficacy in atrial fibrillation and pacemaker-dependent patients is increasingly understood.
- Multimodality imaging plays a crucial role in optimizing CRT outcomes.
Conclusions:
- Refined patient selection and advanced imaging are critical for maximizing CRT benefits.
- Emerging lead technologies hold promise for enhancing CRT effectiveness.
- Continued research and technological innovation are vital for addressing the growing heart failure epidemic.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
707
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
707
Cardiomyopathy II: Dilated Cardiomyopathy
803
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Heart Failure VI: Adjunct Therapies
602
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
602
Cardiopulmonary Resuscitation III: AED Use
1.5K
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
1.5K
Dysrhythmias VI: Management of Dysrhythmias
635
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
635
Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K


